Pfizer Inc. allegedly knew for years that Dilantin can cause Cerebellar Atrophy, a debilitating and progressive brain disorder associated with phenytoin toxicity. Filing a Dilantin lawsuit could allow victims of phenytoin-induced Cerebellar Atrophy to obtain compensation for their injury-related damages.
The nationwide law firm of Bernstein Liebhard is offering free, confidential and no-obligation legal reviews to victims of Dilantin-related Cerebellar Atrophy. To learn more about filing a Dilantin Lawsuit, please call (888) 994-5118.
Dilantin (phenytoin) has been on the market since 1953, and remains one of the most widely-used medications in the world.
The drug is currently indicated to treat grand mal and temporal lobe seizures associated with epilepsy, and to prevent and treat seizures that can occur during or after brain surgery. Dilantin may also be use to control certain types of arrythmias (irregular heart beat), neuropathic pain, and mood disorders like bipolar disorder.
Long-term treatment with phenytoin, the active ingredient in Dilantin, can produce toxic side effects, including:
A growing body of scientific evidence suggests a relationship between Dilantin toxicity and Cerebellar Atrophy. In 1990, for example, researchers noted that patients treated with phenytoin for more than 5 years experienced unsteady gait, speech problems and impaired muscle control due to cerebella nerve cell deficiencies in the brain.
Seizures, including those treated with Dilantin, are also known to cause Cerebellar Atrophy. Nevertheless, a 1994 study found that phenytoin patients had smaller cerebellums overall compared to those treated with a placebo, even after its authors controlled for seizures.
In 2003, another team of researchers observed irreversible deterioration in the cerebellums of patients suffering from phenytoin toxicity.
Pregnant women, infants and the elderly appear to face the greatest danger of Dilantin-induced Cerebellar Atrophy. The risk also increases with long-term Dilantin use and when drug serum levels are above the therapeutic range. However, patients with optimum levels of Dilantin in their blood have also experienced cerebral degeneration,
Cerebella Atrophy occurs when neurons in the brain’s cerebellum become damaged and start to weaken. This type of brain damage is often associated with
Cerebella Atrophy can also occur after exposure to ethanol, certain chemotherapy treatments and phenytoin.
Victims of Cerebellar Atrophy may experience a poor balance, slow movements, tremors and shaking, and unstable eye movements. The most common symptoms include:
Cerebellar Atrophy is occassionally mistaken for a stroke, and some victims might even appear drunk.
Patients with only localized brain damage sometimes recover once they stop Dilantin treatment. However, withdrawal can be dangerous and must be monitored by a doctor. Severe cases of phenytoin-induced Cerebellar Atrophy have resulted in permanent injuries and complications.
According to a multi-plaintiff Dilantin lawsuit filed in October 2018, Pfizer knew that phenytoin could cause Cerebral Atrophy by 2009. But the Dilantin label failed to even mention the disorder until 2016.
Unfortunately, the filing wasn’t the first time Pfizer faced legal action over Dilantin side effects. In 2010, for example, a Massachusetts jury awarded $140 million to a woman who developed toxic epidermal necrolysis, or TEN, from phenytoin.
In January 2010, Pfizer was ordered to pay $10 million to a Dilantin patient who suffered Stevens-Johnson Syndrome (SJS) and cerebellar shrinkage. Just 11 months later, the company settled another lawsuit involving Dilantin and SJS for $4 million.
Patients diagnosed with phenytoin-induced Cerebellar Atrophy prior to January 2016, or their surviving loved ones, may be eligible to file their own Dilantin lawsuit. For your free, no-obligation case review, please fill out the form on this page, or call our office today at (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.